Access to medicines, market failure and market intervention: A tale of two regimes

Global Public Health

Volumn 7, Issue SUPPL. 2, 2012, Pages

  Williams, Owain D ^a  

^a ABERYSTWYTH UNIVERSITY   (United Kingdom)

Author keywords

access to medicines; global drug market; global health; intellectual property rights; trade regimes

Indexed keywords

ARTICLE; COMMERCIAL PHENOMENA; DRUG COST; DRUG DEVELOPMENT; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; HEALTH CARE COST; INTELLECTUAL PROPERTY RIGHT; INVESTMENT; PATENT; PRIORITY JOURNAL;

COMMUNICABLE DISEASES; DRUG INDUSTRY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTELLECTUAL PROPERTY; INTERNATIONAL COOPERATION; POVERTY; WORLD HEALTH;

EID: 84871008773     PISSN: 17441692     EISSN: 17441706     Source Type: Journal    
DOI: 10.1080/17441692.2012.725753     Document Type: Article

References (60)

1. Abbott, F.M. 2002. The TRIPS agreement, access to medicines and the Doha Ministerial Conference. The journal of world intellectual property, 5(1): 15-52.
2. Baker, D., 2004. Financing drug research: what are the issues? 2008 Industry Studies Conference paper. Available from: http://ssrn.com/abstract=1134983 [Accessed 1 Aug 2011].
3. Barder, O., Kremer, M., and Williams, H., 2006. Advanced market commitments: a policy to stimulate investment in vaccines and neglected diseases. Economists' voice, 1-5 Feb, 1-6.
4. Barton, J.H. and Emanuel, E.J. 2005. The patents-based pharmaceutical development process: rationale, problems, and potential reform. Journal of the American medical association, 294(16): 2075-2082.
5. Birn, A.-E. 2005. Gate's grandest challenge: transcending technology as a public health ideology. The Lancet, 366(9484): 514-519.
6. Black, R.E., Bhan, M., Chopra, M., Rudan, I. and Victoria, C. 2009. Accelerating the health impact of the Gates Foundation. The Lancet, 373(9675): 1584-1585.
7. Braga, C.A.P. 1989. Economics of intellectual property rights and the GATT: a view from the South. Vanderbilt journal of transnational law, 22: 243-264.
8. Braga, C.A.P., Fink, C., and Sepulveda, C.P., 2000. Intellectual property rights and economic development. World Bank discussion paper, number 412, Washington, DC: World Bank.
9. Caines, K. 2004. Global health partnerships and neglected diseases, London: DFID Health Resource Centre.
10. Chattaway, J., Hanlin, R., Mugwagwa, J., and Muraguri, I., 2009. Global health social technologies: reflections on evolving theories and landscapes. Innogen Working Paper, 76. Available from: http://oro.open.ac.uk/29783 [Accessed 14 Dec 2011].
11. Danzon, P. and Towse, A. 2003. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International journal of health care finance and economics, 3: 183-205.
12. Drahos, P., 2003. Expanding intellectual property's empire: the role of FTAs. Available from: http://ictsd.net/downloads/2008/08/drahos-fta-2003-en.pdf [Accessed 11 Aug 2011].
13. Drahos, P. and Braithwaite, J. 2002. Information feudalism: who owns the knowledge economy?, London: Earthscan Press.
14. Ecks, S. 2008. Global pharmaceutical markets and corporate citizenship: the case of Novartis' anti-cancer drug Glivec. BioSocieties, 3(2): 165-181.
15. England, R. 2008. The writing is on the wall for UNAIDS. British medical journal, 336(7652): 1072
16. Faunce, T.A. and Lexchin, J. 2007. 'Linkage' pharmaceutical evergreening in Australia and Canada. Australia and New Zealand health policy, 4(8): 1-11.
17. Flynn, S., Hollis, A. and Palmedo, M. 2009. An economic justification for open access to essential medicine patents in developing countries. The Journal of law and medicine, 37(2): 184-208.
18. Grabowski, H. 2002. Patents, innovation and access to new pharmaceuticals. Journal of international economic law, 5(4): 849-860.
19. Hecht, R., Wilson, P. and Palriwala, A. 2009. Improving health R&D financing for developing countries: a menu of innovative policy options. Health affairs, 28(4): 974-985.
20. Helfer, L.R. 2004. Regime shifting: the TRIPS agreement and new dynamics of international intellectual property law making. Yale journal of international law, 29(1): 1-83.
21. Hollis A., 2005. An efficient reward system for pharmaceutical innovation. Available from: http://www.who.int/intellectualproperty/news/en/Submission-Hollis.pdf [Accessed 10 Aug 2011].
22. Hollis, A. and Pogge, T., 2010. The Health Impact Fund: making new medicines accessible for all. Incentives for Global Health. Available from: http://www.healthimpactfund.org [Accessed 5 Aug 2011].
23. Hubbard, T. and Love, J., 2004 A new trade framework for global healthcare R&D. PLoS Biology, 2 2, e52. doi:10.1371/journal.pbio.0020052.
24. Johnston, J. and Wasunna, A. 2007. Patents, biomedical research and treatments: examining concerns, canvassing solutions. Hastings center report, 37: S1-S36.
25. Kapczynski, A. 2009. Harmonization and its discontents: a case study of TRIPS implementation in India's pharmaceutical sector. California law review, 97: 1571-1649.
26. Kazatchkine, M.D., Atun, R. and Lansang, M.-A. 2009. Global health partnerships: a 'pull' mechanism for innovation and new products. Global forum update on research for health, 6: 138-141.
27. Kinsella, N.S. 2001. Against intellectual property. Journal of libertarian studies, 15(2): 1-53.
28. Kremer, M. 2002. Pharmaceuticals and the developing world. Journal of economic perspectives, 16(4): 67-90.
29. Kremer, M. and Glennerster, R. 2004. Strong medicine: creating incentives for pharmaceutical research on neglected diseases, Princeton, NJ: Princeton University Press.
30. Lanjouw, J.O., 1998. The introduction of product pharmaceutical patents in India. "Heartless exploitation of the poor and suffering" NBER Working Paper No. 6366. Available from: http://www.nber.org/papers/w6366.pdf?new_window=1 [Accessed 1 Sept 2011].
31. Mansfield, E. 1986. Patents and innovation: an empirical study. Management science, 32(2): 173-181.
32. McCoy, D., Kembhavi, G., Patel, J. and Luintel, A. 2009. The Bill and Melinda Gates Foundation's grant-making programme for global health. The Lancet, 373(9675): 1645-1653.
33. Moran, M., Ropars, A.-L., Guzman, J., Diaz, J. and Garrison, C. 2005. The new landscape of neglected disease drug development, London: LSE/Wellcome Trust.
34. Moran, M., Ropars, A.-L., Guzman, J., Jorgensen, M., McDonald, A., Potter, S. and Salassie, H.H. 2007. The malaria product pipeline; planning for the future, Sydney: Health Policy Division, George Institute for International Health.
35. Muzaka, V. 2010. Linkages, contests and overlaps in the global intellectual property rights regime. European journal of international relations, 20(10): 1-22.
36. Odell, J.S. and Sell, S.K. 2006. "Reframing the issue: the WTO coalition on intellectual property and public health, 2001". In Negotiating trade: Developing countries in the WTO and NAFTA, Edited by: Odell, J.S. 85-113. Cambridge: Cambridge University Press.
37. Oxfam. 2007. Investing for life. Meeting poor people's needs for access to medicines through responsible business practices. Oxford: Oxfam.
38. Pogge, T. 2009. The Health Impact Fund: boosting pharmaceutical innovation without obstructing free access. Cambridge quarterly of healthcare ethics, 18(1): 78-86.
39. Ravishankar, N., Gubbins, P., Cooley, R.J., Leach-Kemon, K., Michaud, C.M., Jamison, D.T. and Murray, C.J.L. 2009. Financing of global health: tracking development assistance for health from 1990 to 2007. The Lancet, 373(9681): 2113-2124.
40. Ravvin, M. 2008. Incentivizing access and innovation for essential medicines: a survey of the problem and proposed solutions. Public health ethics, 2(1): 110-123.
41. Rosiello, A. and Smith, J. 2004. A sociological economy of HIV(AIDS vaccine partnerships: case studies from Africa and India. International review of sociology, 18(2): 283-299.
42. Rushton, S. and Williams, O.D., 2011. Partnerships and foundations in global health governance. Basingstoke: Palgrave.
43. Selgelid, M.J. 2008. A full-pull program for the provision of pharmaceuticals: practical issues. Public health ethics, 1(2): 134-145.
44. Sell, S.K. 2002. TRIPS and the access to medicines campaign. Wisconsin international law journal, 20(3): 481-522.
45. Sell, S.K. and Prakash, A. 2004. Using ideas strategically: the contest between business and NGO networks in intellectual property rights. International studies quarterly, 48(1): 143-175.
46. Shiffman, J. 2008. Has donor prioritization of HIV(AIDS displaced aid for other health issues?. Health policy and planning, 23(2): 95-100.
47. Stiglitz, J.E., 2007. Prizes, not patents. Project Syndicate. Available from: http://www.project-syndicate.org/commentary/stiglitz81/English [Accessed 19 Jul 2011].
48. Stiglitz, J.E. 1999. "Knowledge as a global public good". In Global public goods, Edited by: Kaul, I., Grunberg, I. and Stern, M.A. 308-328. New York: Oxford University Press.
49. Stiglitz, J.E. 2008. Economic foundations of intellectual property rights. Duke law journal, 57: 1693-723.
50. Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R. and Ford, N. 2002. Drug development for neglected diseases: a deficient market and a public-health policy failure. The Lancet, 359(9324): 2188-2194.
51. UNAIDS. 2012. Together we will end AIDS. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/20120718_togetherwewillendaids_en.pdf [Accessed 5 Jul 2012].
52. UNITAID. 2007. UNITAID Mission. Available from: http://www.unitaid.eu/index.php/en/UNITAID-Mission.html [Accessed 23 Mar 2011].
53. UN Millennium Project. 2005. Prescription for healthy development: increasing access to essential medicines. Report of the Taskforce on HIV/AIDS, Malaria, TB, and Access to Medicines, Working Group on Access to Essential Medicines. Sterling, VA: Earthscan.
54. Waning, B., Kaplan, W., King, A.C., Lawrence, D.A., Luefkens, H.G. and Fox, M.P. 2009. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bulletin of the world health organization, 87: 520-528.
55. WHO, 1999. Guidelines for drug donations. Geneva: WHO. Available from: http://apps.who.int/medicinedocs/en/d/Jwhozip52e [Accessed 14 Dec 2011].
56. Williams, O.D. and Rushton, S. 2011. Are the 'good times' over? Looking to the future of Global Health Governance. Global health governance, 5(1): 1-16.
57. Woodling, M., Williams, O.D., and Rushton, S., 2012. New life in old frames: HIV, development and the 'AIDS plus MDGs' approach. Global public health, 7 10, Supplement 3 (this volume).
58. WTO. 1994. Agreement on trade related aspects of intellectual property rights, Marrakesh Agreement establishing the World Trade Organization, Annex 1C, Legal instruments-results of the Uruguay round, 1869 U.N.T.S. 299, 33 J.L.M. 1197.
59. WTO. 2001. Doha Declaration on TRIPS and public health. Geneva: WTO. Available from: http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm [Accessed 14 Dec 2011].
60. Youde, J. 2011. "The Clinton Foundation and Global Health Governance". In Partnerships and foundations in Global Health Governance, Edited by: Rushton, S. and Williams, O.D. 164-181. Basingstoke: Palgrave.